Results of an Autologous Noncryopreserved, Unmanipulated Peripheral Blood Hematopoietic Stem Cell Transplant Program: A Single-Institution, 10-Year Experience
Authors:
- Guillermo J. Ruiz-ArgüellesGRGuillermo J. Ruiz-Argüelles
- David Gómez-RangelDGDavid Gómez-Rangel
- Guillermo J. Ruiz-DelgadoGRGuillermo J. Ruiz-Delgado
- Alejandro Ruiz-ArgüellesARAlejandro Ruiz-Argüelles
- Beatriz Pérez-RomanoBPBeatriz Pérez-Romano
- Liliana RivadeneyraLRLiliana Rivadeneyra
- 1 December 2003
- journal article
- research article
- Published by S. Karger AG in Acta Haematologica
- Vol. 110 (4) , 179-183
Abstract
Background: Methods to simplify the stem cell transplantation procedures are needed mainly in developing countries. We have previously shown that unprocessed leukapheresis material is useful to restore hematopoiesis after high-dose chemotherapy. Methods: Over a 10-year period in a private practice setting, we prospectively performed autotransplants using noncryopreserved and unmanipulated peripheral blood stem cells mobilized from the bone marrow to the peripheral blood by means of filgrastim and using a single-day conditioning regimen with high dose (200 mg/m2) melphalan. Results: Forty-six individuals were given 50 autografts. The median age of the patients was 33 years (range 8–69). Twenty-two patients with acute leukemia (13 with myeloblastic and 9 with lymphoblastic leukemia), 4 with chronic myelogenous leukemia, 6 with multiple myeloma, 7 with Hodgkin’s disease, 3 with non-Hodgkin’s lymphoma and 4 with metastatic breast carcinoma were included. The median time to achieve >0.5 × 109/l granulocytes was 14 days (range 0–86), whereas the median time to achieve >20 × 109/l platelets was 25 days (range 0–102). The 3,300-day posttransplant survival was 63%, the median posttransplant overall survival was over 3,300 days, the 3,300-day disease-free survival was 50% and the transplant-related mortality was 2%. The procedure was performed entirely on an outpatient basis in the case of 48 autografts (96%). The approximate cost of each graft was 7,500 USD. Conclusion: This simplified method to autograft patients, avoiding in-hospital stays, purging procedures and cryopreservation of the cells, is feasible and results in a substantial decrease in the cost of the autologous hematopoietic stem cell transplantation methods.Keywords
This publication has 4 references indexed in Scilit:
- Non-Cryopreserved Unmanipulated Hematopoietic Peripheral Blood Stem Cell Autotransplant ProgramArchives of Medical Research, 1999
- Non-cryopreserved peripheral blood stem cells autotransplants for hematological malignancies can be performed entirely on an outpatient basisAmerican Journal of Hematology, 1998
- Bone Marrow TransplantationNew England Journal of Medicine, 1994
- Effect of peripheral-blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapyThe Lancet, 1992